| Best practices and benchmarks for intact protein analysis for top-down mass spectrometry DP Donnelly, CM Rawlins, CJ DeHart, L Fornelli, LF Schachner, Z Lin, ... Nature methods 16 (7), 587-594, 2019 | 316 | 2019 |
| Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates JK Nair, H Attarwala, A Sehgal, Q Wang, K Aluri, X Zhang, M Gao, J Liu, ... Nucleic acids research 45 (19), 10969-10977, 2017 | 218 | 2017 |
| Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates MM Janas, I Zlatev, J Liu, Y Jiang, SA Barros, JE Sutherland, WP Davis, ... Nucleic acids research 47 (7), 3306-3320, 2019 | 66 | 2019 |
| The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-Acetylgalactosamine–conjugated small interfering RNA are highly predictable and build confidence … R McDougall, D Ramsden, S Agarwal, S Agarwal, K Aluri, M Arciprete, ... Drug Metabolism and Disposition 50 (6), 781-797, 2022 | 38 | 2022 |
| Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry J Liu, J Li, C Tran, K Aluri, X Zhang, V Clausen, I Zlatev, L Guan, S Chong, ... Bioanalysis 11 (21), 1967-1980, 2019 | 32 | 2019 |
| In vitro drug-drug interaction evaluation of GalNAc conjugated siRNAs against CYP450 enzymes and transporters D Ramsden, JT Wu, B Zerler, S Iqbal, J Jiang, V Clausen, K Aluri, Y Gu, ... Drug Metabolism and Disposition 47 (10), 1183-1194, 2019 | 27 | 2019 |
| Cyclic thiosulfinates and cyclic disulfides selectively cross-link thiols while avoiding modification of lone thiols DP Donnelly, MG Dowgiallo, JP Salisbury, KC Aluri, S Iyengar, ... Journal of the American Chemical Society 140 (24), 7377-7380, 2018 | 25 | 2018 |
| Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide in vivo by mass spectrometry J Li, J Liu, J Enders, M Arciprete, C Tran, K Aluri, LH Guan, J O'Shea, ... Bioanalysis 11 (21), 1955-1965, 2019 | 22 | 2019 |
| The nonclinical disposition and PK/PD properties of GalNAc-conjugated siRNA are highly predictable and build confidence in translation to man S Chong, S Agarwal, S Agarwal, KC Aluri, M Arciprete, C Brown, ... Drug Metabolism and Disposition, 2021 | 19 | 2021 |
| Cyclic Thiosulfinates as a Novel Class of Disulfide Cleavable Cross-Linkers for Rapid Hydrogel Synthesis KC Aluri, MA Hossain, N Kanetkar, BC Miller, MG Dowgiallo, ... Bioconjugate Chemistry 32 (3), 584-594, 2021 | 12 | 2021 |
| Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration KC Aluri, JP Salisbury, JHM Prehn, JN Agar Scientific Reports 10 (1), 3715, 2020 | 10 | 2020 |
| RT-qPCR methods to support pharmacokinetics and drug mechanism of action to advance development of RNAi therapeutics E Castellanos-Rizaldos, CR Brown, S Dennin, J Kim, S Gupta, D Najarian, ... nucleic acid therapeutics 30 (3), 133-142, 2020 | 9 | 2020 |
| GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in vitro and in vivo L Sepp-Lorenzino, AG Sprague, T Mayo, TM Nguyen, SS Morskaya, H Xu, ... Hepatology 62, 224A-225A, 2015 | 9 | 2015 |
| Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing H Jahns, R Degaonkar, P Podbevsek, S Gupta, A Bisbe, K Aluri, J Szeto, ... Nucleic Acids Research 49 (18), 10250-10264, 2021 | 8 | 2021 |
| Reverse transcription quantitative polymerase chain reaction methods to support pharmacokinetics and drug mechanism of action to advance development of RNA interference … E Castellanos-Rizaldos, CR Brown, S Dennin, J Kim, S Gupta, D Najarian, ... NUCLEIC ACID THERAPEUTICS 30 (3), 133-142, 2020 | 5 | 2020 |
| Pharmacokinetic evaluation of poorly soluble compounds formulated as nano-or microcrystals after intraperitoneal injection to mice KC Aluri, K Sigfridsson, A Xue, N Hariparsad, D McGinnity, D Ramsden International Journal of Pharmaceutics 636, 122787, 2023 | 2 | 2023 |
| Cytokine mediated modulation of drug metabolizing enzymes observed at physiologically relevant levels in truvivo hepatocyte model K Aluri, N Hariparsad Drug Metabolism and Pharmacokinetics 55, 100827, 2024 | | 2024 |
| Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression C Vasalou, TA Proia, L Kazlauskas, A Przybyla, M Sung, S Mamidi, ... CPT: Pharmacometrics & Systems Pharmacology, 2024 | | 2024 |
| Aminobenzotriazole inhibits and induces several key drug metabolizing enzymes complicating its utility as a pan CYP inhibitor for reaction phenotyping KC Aluri, M Slavsky, Y Tan, A Whitcher‐Johnstone, Z Zhang, ... Clinical and Translational Science 17 (3), e13746, 2024 | | 2024 |
| Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry (vol 11, pg 1967, 2019) J Liu, J Li, C Tran, K Aluri, X Zhang, V Clausen, I Zlatev, L Guan, S Chong, ... BIOANALYSIS 12 (23), 1709-1710, 2020 | | 2020 |
Christopher R BrownKorro BioVerified email at korrobio.com
